Aptose Biosciences Inc.
APTOF
$1.64
-$0.02-1.21%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.78% | -8.33% | -19.71% | -28.46% | -28.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.18% | -47.37% | -54.27% | -49.85% | -28.51% |
| Operating Income | 46.18% | 47.37% | 54.27% | 49.85% | 28.51% |
| Income Before Tax | 46.11% | 47.58% | 54.78% | 50.34% | 27.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 46.11% | 47.58% | 54.78% | 50.34% | 27.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.11% | 47.58% | 54.78% | 50.34% | 27.31% |
| EBIT | 46.18% | 47.37% | 54.27% | 49.85% | 28.51% |
| EBITDA | 46.17% | 47.32% | 54.24% | 49.83% | 28.46% |
| EPS Basic | 90.54% | 86.50% | 85.02% | 79.54% | 61.01% |
| Normalized Basic EPS | 90.54% | 86.50% | 85.02% | 79.54% | 61.01% |
| EPS Diluted | 90.54% | 86.50% | 85.02% | 79.54% | 61.03% |
| Normalized Diluted EPS | 90.54% | 86.50% | 85.02% | 79.54% | 61.01% |
| Average Basic Shares Outstanding | 349.73% | 339.36% | 299.04% | 213.53% | 124.09% |
| Average Diluted Shares Outstanding | 349.73% | 339.36% | 299.04% | 213.53% | 124.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |